EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, ...

Beam Therapeutics (BEAM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

BMS isn’t the only firm trying to use degraders to tackle sickle cell disease. Novartis has a Wiz-targeting glue degrader, ...

Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...

Only one quarter of patients living with sickle cell disease are prescribed disease modifying therapies, particularly newer ...

The latest announcement is out from Beam Therapeutics ( (BEAM) ).

J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...

When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...

Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...

This results in red blood cells being destroyed, which is known as hemolytic anemia ... People with beta thalassemia trait will have elevation in hemoglobin A2 and/or F (fetal). There is no simple ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...

Beam Therapeutics (BEAM) announced new data for its Engineered Stem Cell Antibody Evasion, or ESCAPE, conditioning platform.